October 29, 2009
In preliminary results announced at a recent meeting of the American Academy of Ophthalmology, Epimacular Brachytherapy has been shown to decrease the need for injections of anti-VEGF in treating neovascular Age-Related Macular Degeneration (AMD). Now being tested by NeoVista, Inc., preliminary results show that a single procedure of Epimacular Brachytherapy can further improved visual acuity in a majority of cases, while decreasing the number of anti-VEGF injections required. These results are based on Optical Coherence Tomography imaging after the brachytherapy procedure.
What do these new findings mean to people with neovascular AMD? Of the patients enrolled in the study, 63% experienced improvement in their visual acuity while 50% of patients gained 5 or more letters of visual acuity at 6 months.
“This is the first study of its kind designed to evaluate the potential role of our device in decreasing the current burden of treatment while maintaining or improving visual acuity,” said John N. Hendrick, President and CEO of NeoVista. “Data from recent randomized trials suggest that most patients suffering from neovascular AMD will require treatment on an ongoing basis for an indefinite period of time. We are very excited that our device has the potential to significantly decrease the number of injections administered in this patient population and may also improve visual acuity in a majority of cases.”
For more information about the company, or this novel neovascular AMD therapy, visit the company’s Web site at www.neovistainc.com.
Articles you might like:
Filed under Elderly care